Crisil Limited has upgraded its rating to CRISIL BB/STABLE/ CRISILA4+
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
CRISIL has revised its credit rating on Samrat Pharmachem's bank facilities to CRISIL BB/Stable/CRISIL A4+ from CRISIL BB+/Negative/CRISIL A4+. The long-term rating was lowered by one notch (BB+ to BB), while the outlook improved from Negative to Stable. The short-term rating of CRISIL A4+ remains unchanged. Although the company filing describes the action as an 'upgrade,' the actual long-term rating tier has moved down, even as the outlook has stabilised.
Mixed signal for investors — the one-notch cut in the long-term rating suggests slightly weaker credit standing, but the shift from a Negative to Stable outlook removes near-term downgrade pressure. The stock may see limited immediate reaction given the offsetting signals.